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I. SUMMARY

While abundant fears mark the pathways for the development of the New
Biology, humanity's dehumanization and depersonalization will not be
fostered-in reality-as a consequence of the continuing quest for mastery of
the genetic code through pursuit of the Human Genome Initiative. Indeed, if
actions are undertaken and performed here with the goal of minimizing human
suffering and maximizing the social good, then the noble integrity of
evolutionary and genetic progress will be preserved and the "slippery slope"
of careless and irrational action will be avoided totally.
Obviously, attendant to the freedom to undertake research into the exciting
frontiers of the New Biology is a co-existent responsibility to pursue the work
in a reasonable and rational manner. The real-although often
exaggerated-threats to genetic privacy, and the resulting forms of genetic
discrimination, posed as a consequence of research in this field, can be
contained by careful development and application of legal norms through
legislative schemes at the state and federal levels of government. In

1B.S., J.D., Indiana University; LL.M. Columbia University. Professor of Law, The
Catholic University of America.
This essay is a revised and extended version of a paper entitled, "Biological
Determinism or Genetic Discrimination," presented at the 10th World Congress on
Medical Law in Jerusalem on August 31,1994.
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partnership, law and science should seek to develop a contemporary agenda
for social change that also seeks to fulfill socio-political goals.
When viewed as but a tool for enhancing the health of the nation's citizens,
and of engineering humanity's genetic weaknesses out of the line of
inheritance, biological determinism is an absolute necessity for trans-national
survival in the 21st century. Simply stated, healthier and genetically sound
individuals have a much better opportunity for pursuing and achieving the
"good life" and making a significant contribution to society's greater well-being
or, in other words, social good.
II. PROBLEMS OR OPPORTUNITIES

The publication of Aldous Huxley's Brave New World in 1946 predated the
2
discovery by James Watson and Francis Crick of deoxyribonucleic acid (DNA)
by seven years. Commentators to this day continue to view the significance of
advances in recombinant DNA (rDNA) technology through the lens of
Huxley's totalitarian society,3 a genetic caste system made possible by genetic
technology.4 The alternative characterization of such technology as a grail to
treat or heal inherited diseases is perhaps less alarming but similarly fails to
adequately describe the current state of technology both from the perspective
5
of identifying specific genetic traits and from that of developing therapy.
6
Nevertheless, in 1993, the fortieth anniversary of the discovery of DNA, the
Human Genome Project continues its mapping of the human genome, 7 and the
2

James Watson & Francis Crick, Genetic Implications of the Structure of

DeoxyribonucleicAcid, 171 NATURE 964 (1953).

3Kimberley Nobles, Birthrightor Life Sentence: Controllingthe Threatof GeneticTesting,
65 S. CAL. L. REv. 2081 (1992). See GEORGE P. SMITH, II, THE NEW BIOLOGY: LAW, ETHICS
AND BIOTECHNOLOGY (1989).
4

Such rDNA advances include germ-cell or germ-line therapy, whereby genes
within sperm or eggs are replaced or repaired to the effect that such modified genetic
material is passed on to the next generation. U.S. CONGRESS, OFFICE OF TECHNOLOGY
ASSESSMENT, BIOLOGY, MEDICINE, AND THE BILL OF RIGHTS--SPECIAL REPORT 40
(OTA-CIT-371 1988). In contrast, somatic cell therapy will not cause inherited or
inheritable changes. It mightprovide, however, a means of replacing the defective gene
in the bone marrow cells of a child affected by genetic immune deficiency. If successful,
such therapy would "cure" the child but would have no effect on his or her own
offspring. Id. See also The Aim is to Get Genes to Do the Work: Newsday Interview with James
D. Watson, NEWSDAY, July 6, 1993, at 59. See generally D. NELKIN & L. TANCREDI,
DANGEROUS DIAGNOSTICS: THE SOCIAL POWER OF BIOLOGICAL INFORMATION (1989);
GUSTAV NOSSAL, HUMAN GENETIC INFORMATION: SCIENCE, LAW & ETHICS (1990).
5

THE CODE OF CODES: SCIENTIFIC AND SOCIAL ISSUES IN THE HUMAN GENOME PROJECT

(DanielJ. Kevles & Leroy Hood eds., 1992). See generallyGeorge P. Smith, II, Uncertainties
in the SpiralStaircase:Metaethics and the New Biology, 41 THE PHAROS MED. J.10 (1978).
6

NEWSDAY, supra note 4. Secalso ChangingYour Genes, THE ECONOMIST, April 25,1992

at 11; Leon Jaroff, Making the Best of a Bad Gene, TIME, Feb. 10, 1992, at 78.
7

See Carol Lee, Creatinga Genetic Underclass: The Potentialfor Genetic Discrimination
by the Health InsuranceIndustry, 13 PACE L. REv. 189,195 (1993).
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accelerated pace of mapping that began in the early 1970's 8 is expected to
continue due to innovations in genome mapping and sequencing. 9
The salutary effect of this technology-the ability to catalog and analyze the
genotype of a particular individual-creates the potential for abuse of such
information. Indeed, for some, the eugenics movement1 0 to this day casts a
shadow over the Human Genome Project. The risks of abuse engendered by
the mapping of the human genome and emergent rDNA technology do not
extend to social engineering and development of a "superior" human, a process
necessitating germ-line modification. Rather, the potential abuse may result
from discrimination based on the dissemination of key information about the
genotype of an individual-information which reveals the risk factors inherent
in that individual.11 Genetic data is a particularly sensitive category of health
care information. 12 Unlike information about a specific transient condition or
illness, data pointing to a genetic disorder will affect, and may stigmatize, a
person throughout his or her entire life.13 The handling of genetic information
by the state or its agents, therefore, implicates individual liberty interests
deriving from fundamental constitutional rights to equality and privacy.14 In
8

Clive Cookson, The Men Who Would Play God: Unravelling the secrets of the human
gene could transform human life. But the possibilitiesfor abuse of this power are terrifying, FIN.
POST (Weekly Edition), Feb. 10,1992, at S37.
9

Daniel Kevles & Leroy Hood, The Deoxyribonucleic Acid Test, S.F. CHRON., Dec. 6,
1992, § Z1, at 8.
10

The basic idea of eugenics was to improve the human gene pool by increasing the
number of supposedly desirable human beings ("positive" eugenics) and getting rid of
undesirable ones ("negative" eugenics). Id. In Nazi Germany, the eugenics movement
rationalized policies of mass sterilization and ultimately the creation of death camps for
the extermination of individuals deemed undesirable by virtue of ethnicity, religion, or
sexual orientation. Similarly, in the United States, many states enacted sterilization laws
justified in large part by eugenic principles. In California alone, 6,255 individuals were
sterilized by 1929. Most of these laws were overturned, however, by a decision of the
United States Supreme Court in 1942. Id. See Skinner v. Oklahoma, 316 U.S. 535 (1942).
11
See Paul R. Billings et al., Discriminationas a Consequenceof Genetic Testing, 50 AM.
J. HUM. GENETICS 476, 479, 481 (1992). The findings of this study affirm the existence of
discrimination against individuals who are completely asymptomatic, their only
"abnormality" being in their genotype. Indeed, it appears that genetic conditions are
regarded by many social institutions (i.e., insurance companies) as extremely serious,
disabling, or even lethal conditions. See generallyAndrea DeGorgey, The Advent of DNA
Databanks:ImplicationsforInformationPrivacy, 16 AM. J.L. & MED. 381 (1990).
12
Lori B. Andrews, The Future of Confidentiality of Genetic Information, in MEDICAL
GENEICS: A LEGAL FRONTIER 209 (1987); See George P. Smith, II, Genetics, Eugenics and
Public Policy, 1985 So. ILL. U. LJ. 435.
13

Andrews, supra note 12, at 187-88, 209. Unlike an infectious disease, a genetic
disorder is generally immutable. Thus, an inappropriate disclosure may cause serious
financial, emotional and perhaps even physical harm to the individual in question.
14
1d. See Neil A. Holtzman, Recombinant DNA Technology, Genetic Tests and Public
Policy,42 AM. J. HUM. GENETICS 624 (1988). See George J.Annas, PrivacyRules for DNA
Databanks:ProtectingCoded Future Diaries, 270 JAMA 2346 (1993). See generally George

JOURNAL OF LAW AND HEALTH

[Vol. 9:121

this context genetic discrimination has been defined as "discrimination against
an individual or against members of that individual's family solely because of
real or perceived differences from the 'normal' genome in the genetic
constitution of that individual."15 Individuals identified as at risk are:
(1) those.., who are asymptomatic but carry a gene(s) that increases
the probability that they will develop some disease, (2) individuals
who are heterozygotes (carriers) for some recessive or X-linked genetic
condition but who are and will remain asymptomatic, (3) individuals
who have one or more genetic polymorphisms that are not known to
cause any medical condition, and (4) immediate relatives
of
16
individuals with known or presumed genetic conditions.
Because the individuals who are likely to be discriminated against are
asymptomatic or presymptomatic and are, therefore, not readily identified,
genetic discrimination is most likely limited to two contexts: employment
and insurance.1 7 Both employers and insurers may believe such discrimination
is warranted for the profitable conduct of business. 18 Furthermore, both

P. Smith, II, Biotechnology and the Law: Social Responsibility in Freedom of Scientific
Investigation, 36 MERCER L. REv. 437 (1988).
One leading commentator has proposed four basic privacy rules for DNA
databanks. First, no such databanks should be created or commence storing DNA
samples until public notice and justification are given for establishing such a bank, a
privacy impact statement is filed with the designated public (or licensing) agency; and
proof is provided that such a bank advances a significant medical or societal goal.
Second, no collection or storage of DNA samples can be undertaken without prior
written agreement setting forth the purposes and uses (including commercial)
permitted of the samples, and recognized guarantees of individual access to all samples
and records thereof are given, together with a right to not only correct inaccurate
information but an additional right recognized to order the destruction of the sample
should the databank change significantly its identity, or for that matter, cease operation
altogether. Third, strict security policies should be set that allow the DNA samples to
be used exclusively for the purposes for which they are collected-with access by third
parties being controlled strictly. Fourth, mechanisms should be developed which allow
notification and counsel to those whose DNA samples are being stored when new
information is made available that may have an important health impact on such
individuals. Annas, supra note 14, at 2349.
15

Marvin R. Natowicz et al., Genetic Discrimination and the Law, 50 AM. J. HuM.
GENETICS 465, 466 (1992). The authors distinguish genetic discrimination from
discrimination based on disability caused by altered genes and thereby clarify the point
that genetic discrimination is not based on any notion of the present function of the
individual. Ratherthe discriminating partyrelies on that individual's genotype to assess
risk of future dysfunction.
16Id.
17

1d. See U.S. CONGRESS, OFFICE OF TECHNOLOGY AssEssMENT, GENEIC MoNITORING
AND SCREENNG IN THE WORKPLACE, (OTA-BA-455 1990).
18

See Natowicz, supra note 15, at 467.
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employers and insurers normally have access to detailed medical records of
employees and customers. 19
For example, an employer may reject a job applicant based on information
obtained through genetic testing for several reasons: increased medical and
insurance premiums, absenteeism, lowered productivity, increased risk in the
line of duty and increased liability for workers compensation. 20 In the area of
insurance, genetic testing potentially undermines the principle that both the
insurer and the insured ought to possess equal knowledge of a particular
insured's risk of becoming ill. 21 The availability of the genotype of a particular
individual either to the insurer or to that individual alone presents the
possibility of adverse selection. 22 For example, an individual who knows
he/she is at risk for developing Huntington's chorea will buy a greater amount
of life or health insurance as he/she knows that he/she is at greater risk of
death or serious illness.23 Conversely, insurers will either refuse to offer
24
coverage or drop those individuals in a genetic high-risk category.
Although arguably fair when an individual chooses to engage in high risk
activity such as smoking or sky-diving, the prospect of refusing to provide
insurance to individuals because of a genetic trait is inequitable and contrary
to public policy. 25 First, carriers of defective genes may never develop full
symptoms that affect their ability to function. 26 More importantly, however,

19
1d. See Mark A. Rothstein, Genetic Screening in Employment: Some Legal, Ethical and
Societal Issues, 1 INT'L J. BIoETHIcS 239 (1990).
20

Nobles, supra note 3, at 2089. A more accurate measure of safety risk instead of

utilizing genetic testing would be a test of an individual's actual capacity to function in
a safety sensitive job. Council on Ethical and Judicial Affairs, Use of Genetic Testing by

Employers, 266 JAMA 1827,1828 (1991).
21
Nobles, supra note 3, at 2089. Over time, as the costs of genetic testing decrease and
their degree of accuracy increases, insurers may well be expected to find itnot only cost
effective to screen genetically prospective clients but indeed a competitive necessity.

The central problem with insurers, either in performing genetic testing themselves or
obtaining genetic information about such tests performed independently, is that this

practice would lead, in all likelihood, to discrimination (i.e., higher premiums or
rejection altogether) against those who carry genes or genetic markers which dispose
them to future illness.
22

1d.

23

1d.

24

Nobles, supra note 3, at 2090. Florida, Louisiana, New Jersey and North Carolina
have enacted legislationprohibiting discriminationin employmentand insurancebased

on carrying the sickle cell trait, hemoglobin C trait, thallasemia, Tay-Sachs or cystic
fibrosis. FLA. STAT. § 448.076 (1991); LA. REV. STAT. §§ 22:652.1.23:1002A (1992); N.J.
STAT. §§ 10:5-12, 10:5-5 (1992); N.C. GEN. STAT. §§ 58-51-45, 58-58-25, 95-28.1 (1992).
25
26

Nobles, supra note 3, at 2090.
1d.
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such disparate treatment and resulting risk minimization vitiates the purpose
27
of traditional private insurance as a risk-spreading mechanism.
III. THE HUMAN GENOME INITIATIVE

The human genome refers simply to the chromosomal collection of
twenty-three pairs of chromosomes that all humans carry, within which all
human genes reside and, more specifically, to those genes that contribute
directly to traits such as height, eye color, and the shape of body parts as well
as to human behavior. Diseases develop when alterations of the genes, known
as mutations, occur.28 In all, more than 2,000 disease conditions have been
29
found to have their origins in single gene defects.
The Human Genome Initiative is an undertaking coordinated by the United
States Department of Energy and the National Institutes of Health and funded
by the U.S. Congress that will complete "mapping" all 50,000 to 100,000 human
genes within fifteen years. Although not fully funded at the $3 billion set
originally, Congress has funded the project sufficiently for there to be every
reason to conclude the project will meet its deadline. 30 As of March, 1993, some
2,736 of the targeted genes had been in fact "mapped" or, in other words, located
precisely on one of the twenty-three chromosomes. 31
The driving motive behind the Human Genome Initiative is, then, quite
simple and direct: the identification and eradication of all genetically based
disease. With more than 2,000 conditions being recognized as having their
origins in single gene defects, 32 the ultimate success of the Initiative holds
awesome opportunities for improving the health of all world citizens and
minimizing human suffering from disease. 33 Yet, the secrets of the
genome-when revealed-will generate a whole array of "what-if' fears: from

27

1d.

28Jon Beckwith, Foreward: The Human Genome Initiative: Genetics' Lightning Rod, 17
AM. J.L. & MED. 1, 2 (1991). See MAXINE SINGER & PAUL BERG, GENES & GENOME" A
CHANGING PERSPECTIVE (1991).
29

Catherine M. Valerio Barrad, Genetic Information and Property Theory, 87 Nw. U. L.
REV. 1037, 1043 (1993).
30
Seth Lubove, Genomic Wildcatters, FORBES, Feb. 3,1992, at 97; James D. Watson, The
Human Genome Project:Past, Presentand Future, 248 SCIENCE 44 (1990).
31

David Brown, Filling in Gene Maps, But Farfrom Home, WASH. POST, Mar. 8, 1993,

at A3; Daniel E. Koshland, Jr., SEQUENCES AND CONSEQUENCES OF THE HUMAN GENOME,

246 SCIENCE 189 (1989).
In 1990, the federal government's Center for Biologics, Evaluation and Research at
the Food and Drug Administration approved efforts to undertake human gene therapy.
See Medical Research Council, HUMAN GENOME RESEARCH: A REVIEW OF EUROPEAN AND
INTERNATIONAL CONTRIBUTIONS (Diane J. McLaren, ed. 1991).
32
33

Barrad, supra note 29, at 1043.

See George P. Smith, 1I,Manipulatingthe Genetic Code: JurisprudentialConundrums,
64 GEO. L.J. 697 (1976).
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fear of the unbridled use of genetic information to advance a program of
positive eugenics 34 to concerns that disclosure of an individual's genetic profile
and his susceptibility to illness (even alcoholism) will, in turn, form the basis
for discriminatory action or stigmatization. There is concern that the disclosure
of genetic information could result in a possible refusal by an insurer to pay
medical costs if one were to elect not to undergo a recommended treatment or
if a child with a prenatally identified genetic defect were to be born. 35
Equally worrisome is the fear that the widespread delineation of genetic
profiles will result in the centralization of that genetic information-much as
today credit information is centralized. Since DNA sequence databases are
prone to error, there is also concern that even in the event gene mapping were
to become routine, "comparison of an individual's genetic profile to an
error-ridden prototype could have the same stigmatizing effect as do false
positives on drug tests and tests for the -IV antibody.

'3 6

A. The Perilsof Genetic Knowledge
Once a "disease gene" is discovered, the release of the information normally
incorporates a suggestion that treatments to arrest it are forthcoming. Yet,
discovering the mechanism of a disease is not the same as knowing how to
change that mechanism. With genetic information of this type, however, at least
a chance is created for developing an effective therapy to combat the genetic
37
disease.
The "heuristics of fear" all too often blot out rational analysis of emerging
genetic knowledge 38 and do little to satisfy the need to promote medically and
ethically informed public discussion 39 within "communities of moral
discourse" where scientific, as well as medical, ethical and political issues can
be discussed "by informed and intelligent persons who represent different
perspectives on the nature of humanness."40 Caution should always be the
watchword in examining genetic assumptions, and oversimplification of
41
genetic findings should be avoided.

34

See GEORGE P. SMrI,

II,GENETICS, ETHICS ANDTHE LAW, Ch. 5 (1981). See also PHILIP

REILLY, GENETICS, LAW AND SOCIAL POLICY, 120 & Ch. 5 (1977).
35

Barrad, supra note 29, at 1046.

36

1d. at 1047.

37

Brown, supra note 31.

38

See INSEL VERLAG, Frankfurt am Main, THE IMPERATIVE OF RESPONSI]ILITY: IN
SEARCH OF AN ETHIC FOR THE TECHNOLOGICAL AGE (Hans Jonas trans., 1984).
39

James M. Gustafson, Genetic Therapy: Ethical and Religious Reflections, 8J. CONTEMP.
HEALTH L. & POL'Y 183, 190 (1992).
40

1d. at 199-200.

41

Rochelle Cooper Dreyfus & Dorothy Nelkin, The Jurisprudenceof Genetics, 45 VAND.

L. REV. 313, 347-48 (1993).
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As much as law should seek to avoid ambiguity, it should not rely on science
for definitive answers. Science, within its own sphere, simply does not offer
unambiguous answers. 42 Two forms of uncertainty are inherent in any
scientific undertaking. The first is conceptual and derives from fundamental
changes in those concepts engendered by the new biotechnologies. The second
is termed occurrence and applies to select issues that cannot be readily
addressed. 43
The image of neutrality that science has sought to cultivate or "sell," is largely
a myth created in an attempt to maintain autonomy and thus blunt increasing
pressures from both church and state for intervention and control. 44 Indeed,
the history of science is replete with cases where not only the choice of research
topics but the nature of scientific theories as well as the representation of results
from research have been socially constructed and shaped by cultural forces to
45
reflect various societal assumptions of the times.
IV. TOWARD A PRINCIPLE OF BIOLOGICAL DETERMINISM
In today's society, a new and discernible preoccupation with biological
determinism is all too evident. This preoccupation is spurred by successes in
developing genetic tests that have found the markers indicating
predispositions to certain single gene disorders such as Huntington's disease,
and the hopes that complex conditions such as cancer, drug dependency and
mental illness will be-with the successes of the Genome Project-predictable.
Building upon the limited successes with Huntington's chorea, a number of
states now mandate newborn infant genetic testing for conditions such as
46
phenylketonuria (PKU).
Biological determinism evolves from the principle of genetic essentialism,
which posits that personal traits such as mental illness, homosexuality,
aggressive personality, exhibitionism, dangerousness, shyness, and stress have
a genetic or biological disposition and, indeed, are predictable and
determinable at conception. Thus, the social context in which the traits are
42
43

d. at 343-45.
President's Commission for The Study of Ethical Problems in Medicine &

Biomedical & Behavioral Research, SPLICING LIFE: A REPORT ON THE SOCIAL & ETHICAL
ISSUES OF GENETIC ENGINEERING wrn HuMAN BEINGS 22 (1982).
44
Dreyfus & Nelkin, supra note 41, at 339. See, e.g., the evolution of Darwin's theory
of Natural Selection into a theory of Social Darwinism as a biological defense of the
changing forces of industrialization and the extension of Gregor Mendel's theories of
genetics and the eugenic principles of Francis Galton to prove deviant behavior and low
intelligence as but aspects of heredity. Id. at 339, 340.

45WASH. POsT, Nov. 14, 1990, at 1, col. 5. See generally W. French Anderson, Human
Gene Therapy: Scientific and Ethical Considerations,10 J.MED. & PHIL. 275 (1985).
46

Dreyfuss & Nelkin, supra note 41, at 314. For an historical overview of early state
mandated PKU testing between 1963 and 1968 and the state legislative citations to the
forty-three states where such genetic testing is required, see Reilly, supra note 34, at 37
passim, 49-52, Ch. 4 (1977).
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manifested is minimized under this principle.47 In a word, biological
determinism recognizes essentially that one's fate is determined by his or her
genetic inheritance. 48
A. ContemporaryPerspectives
In 1992 Louis Harris and Associates conducted a survey for The March of
Dimes polling one thousand people in the United States regarding their views
of genetic testing and gene therapy. Seventy-nine percent of those polled, while
not in fact understanding totally what the two issues were all about, expressed
their willingness to undergo gene therapy if necessary. Eighty-eight percent of
these polled allowed that they would have their children undergo such therapy
in order to prevent or cure a genetic disease that would usually be fatal if not
found through testing. Approximately three quarters of those in the poll
expressed their concern that gene therapy be undertaken only according to
"strict regulations." And, interestingly, more than half in the survey stated their
belief that when a genetic disease is discovered, someone needs to be appraised
of this fact. Only about a third thought an employer should be advised of the
genetic disease. Yet ninety-eight percent concluded one's spouse or fiancd
should be told, and fifty-eight percent concluded insurers should be informed.
Finally, forty-seven percent of those surveyed favored experimental gene
therapy if its goal was to improve therapeutically ultimate physical
characteristics, while forty-two percent would allow it if its goal was to
improve a child's intelligence. 49
V. THE HUMAN GENOME PRIVACY ACT: A MODEL LEGISLATIVE SOLUTION?

In the area of privacy, there has been only one legislative proposal which, as
a model statute, merits study. The Human Genome Privacy Act (HGPA) was
introduced before the House of Representatives by Representative John
Conyers on September 13, 1990.50 Although no action was taken on the bill
following its introduction, its language responds in many respects to the

47Dreyfuss & Nelkin, supra note 41, at 320-21. See Owen D. Jones, Sex Selection:
Regulating Technology Enabling the Predeterminationof a Child's Gender, 6 HARV. J.L. &
TECH. 1, 21 (1992) where the principal justification of sex selection is that its use serves
to reduce or eliminate "certain sex-linked diseases, such ashemophilia, Cooley's anemia,

Down's syndrome, and more than 400 others, that increase aggregate social anxiety and
tax society's medical and financial resources."
48
Dr. James Watson, Director of the Human Genome Initiative, said, "Our fate is in
our genes." Leon Jaroff, The Gene Hunt, TIME, Mar. 20, 1989, at 62, 67.
49

Sandy Rovner, Many Americans Say Gene Therapy Okay, WASH. POST HEALTH MAC.,
Sept. 29, 1992, at 5. See generally Howard Markel, The Stigma of Disease:Implications of
Genetic Screening, 93 AM. J. MED. 209 (1992). See also Philip Elmer-Dewitt, The Genetic
Revolution, TIME, Jan. 17, 1994, at 46.
50
H.R. 5612, 101st Cong., 2d Sess. (1990). This legislation is no longer pending. In
October, 1992, Congress adjourned sine die. Thus, all unpa ssed bills pending at that time
died. Neither this HGPA nor similar legislation has been reintroduced.
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problems of confidentiality of genetic information in the workplace. It may be
fully expected that similar legislation will be proposed over time. 51 The
purpose of the bill was "to safeguard individual privacy of genetic information
from the misuse of records maintained by agencies or their contractors or
grantees for the purpose of research, diagnosis, treatment, or identification of
genetic disorders."52 The bill would have provided individuals access to
records concerning their genome as maintained for any purpose by agencies
of the federal government. 53 The language of this proposed legislation may be
studied as a potential model for future legislation both at the federal and state
levels. 54
From a policy perspective, the HGPA would overlap with two important
federal statutes. In lieu of enacting new legislation, Congress could easily
amend either the Americans with Disabilities Act (ADA) 55 or the Privacy Act 56
51

Lori B. Andrews & Ami S. Jaeger, Confidentiality of Genetic Information in the

Workplace, 17 AM. J.L. & MED. 75, 108 (1991).
52
H.R. 5612, supranote 50.
53

1d.

54Preexisting federal legislation protecting against discrimination as to individuals
with mental and physical impairment and limiting the type of information the
government may collect is found in the Americans with Disabilities Act of 1990, 42
U.S.C.A. §§ 12011-12213 (West Supp. 1992) and the Privacy Act of 1974, 5 U.S.C. § 552a
(1988) respectively.
55
The Americans with Disabilities Act of 1990, 42 U.S.C.A. §§ 12101-12213 (West
Supp. 1992). Specifically, "the ADA prohibits employers from discriminating against
individuals who have, or have had a history of, a disability that involves a mental or
physical impairment that limits a major life activity." Charles B. Gurd, Whether a Genetic
Defect Is a Disability Under the Americans with Disabilities Act: Preventing Genetic
Discriminationby Employers, 1ANNALS HEALTH L. 107,118 (1992). Section 12112(a) of the
Act states specifically that:
[n]o covered entity [employer, employment agency, labor organization
or joint labor-management committee excluding the federal government]
shall discriminate against a qualified individual with a disability because
of the disability of such individual in regard to job application procedures,
the hiring, advancement, or discharge of employees, employee compensation, job training, or other terms, conditions and privileges of employment.
42 U.S.C.A. § 12112(a) (West Supp. 1992).
Section 12112(d)(2)(A) prohibits preemployment medical examinations.
Accordingly, no preemployment questionnaires may be used by prospective employers
nor may they inquire of potential employees whether they have any medical conditions
such as epilepsy, diabetes or hypertension. Only questions that focus on specific,
job-related functions may be asked of applicants. 42 U.S.C.A. § 12112(d)(2)(B) (West
Supp. 1992). Statutory prohibition against preemployment medical examinations will
assist greatly in curing abuses in discriminatory hiring that would otherwise be based
on genetic testing.

56Privacy Act of 1974, 5 U.S.C. § 552a (1988). The Privacy Act restricts the type of
information that the federal government may collect. Thus, it provides that the
government may retain only the minimal amount of records possible:
(e) Agency requirements-Each agency that maintains a system of records
shall-
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in order to include relevant provisions of the HGPA. Although addressing
analogous discrimination and privacy issues, the ADA and the Privacy Act fall
short of extending explicit protection to asymptomatic individuals with
57
abnormal genotypes.
Regarding disabilities under the ADA, the current policy is "can't ask, don't
tell." The major uncertainty with this policy is "whether a genetic trait that has
not manifested itself counts as a disability within the meaning of the statute."58
It would appear that the most fruitful path in the legislative arena would be
by amendment to these legislative schemes. As amended, these statutes should

(1) maintain in its records only such information about an individual as is
relevant and necessary to accomplish a purpose of the agency required to
be accomplished by statute or by executive order of the President;
5 U.S.C. § 552a(3)(1). Furthermore, subject to certain exceptions, the Act provides for

protections from disclosure:
(b) Conditions of disclosure-No agency shall disclose any record which is
contained in a system of records by any means of communication to any
person, or to another agency, except pursuant to a written request by,
or with the prior written consent of, the individual to whom the record
pertains....
5 U.S.C. § 552a(b). This legislation, however, only serves as a protection against
disclosure by the federal government.
57

See Gurd, supra note 55, at 118. Because of the statutory requirement of some past
or present dysfunction, many individuals who have a genetic defect are not covered.
Furthermore, the ADA may be "inapplicable to carriers or individuals receiving
treatment to prevent gene expression." Id.Accordingly, the ADA provides no protection
from "discrimination based on an individual's genetic profile." Id. See also Larry 0.
Gostin, Genetic Discrimination:The Use of Genetically Based Diagnosticand PrognosticTests
by Employers and Insurers, 17 AM. J.L. & MED. 109, 123 (1991) (explaining that a genetic
condition which does not cause substantial impairment may not constitute a disability
as defined under the Act).

The agency charged with enforcing the ADA, the Equal Employment Opportunity
Commission, has determined that there is no individual coverage under the law until
oneis determined tobe symptomatic. Thus, presymptomatic individuals with late-onset
disorders as, for example, adult polycystic kidney disease, would have no coverage
under the Act. Similarly, those "carriers of recessive disorders such as cystic fibrosis..
. are [also] not covered and could be denied employment." Neil A. Holtzman & Mark
A. Rothstein, Invited Editorial: Eugenics and Genetic Discrimination, 50 AM. J. HUM.
GENETICS 457, 458 (1992). See also E. Juengst, Prioritiesin Professional Ethics and Social
Policyfor Human Genetics, 266 JAMA 1835 (1991).
What can be seen in the disability rights movement is a direct ideological challenge
to medical genetics or genetic determinism. It has been urged that rather than prevent
the birth of persons with significant disabilities (e.g., blindness), society should change
the ways in which it views these individuals and thus accept them as equals. ROBERT
CoOK-DEEGAN, THE GENE WARS: SCIENCE, POLITICS AND THE HUMAN GENOME 252 (1994).
With respect to the Privacy Act, the main defect is that it restricts only the types of
information that may be collected by the federal government. However, its provisions
seem to apply broadly, and would thus include genetic information with other types of
personal data. See Andrews & Jaeger, supra note 51, at 101.
58Richard A. Epstein, The Legal Regulation of Genetic Discrimination:Old Responses to
New Technology, 74 B.U. L. REV. 1, 13-18 (1994).
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recognize the fundamental importance of privacy and equality rights while
explicitly extending the protection of these principles to problems of
discrimination based on disclosure and dissemination of genomic information.
Such amendments to an established statutory framework would simplify the
process of effectuating newly enacted protections, rather than establishing a
new area of law subject, in turn, to the promulgation of complex regulations
and interpretative judicial clarification.
VI. INTERNATIONAL STRATECIES

At the international level, three strategies are available: (1) imposition of an
international moratorium on the use of genetic information obtained from
testing in connection with applications for employment and private insurance;
(2) development of a common set of principles under the planned Bioethics
Convention of the Council of Europe that would guide the future collection
and use of genetic information; and (3) inclusion within Articles 2 and 26 of the

United Nations International Covenant on Civil and Political Rights, which
prohibits discrimination on the grounds of race, sex or religion, provisions
applying to genetic discrimination. 59
As to the first strategy, enforcement of a moratorium would be difficult, but
certainly reasonable since there is no regular practice of genetic testing being
undertaken presently throughout the world community. Even though the
Council of Europe has no enforcement powers, the second approach would
appear to be the most achievable. Consensus might be more readily attained
since the Steering Committee on Bioethics of the Council has recently, after two
years, produced a draft convention and referred it to European governments
for consultation. 60 The third alternative would be merely palliative since, again,
there would be no supervisory or enforcement powers other thanselfregulation
among the signatories.
VII. A NEw PARTNERSHIP

While the Human Genome Initiative will provide startling genetic maps, it
remains for the law to sequence or identify the policy issues inherent in the
complex programming of medical genetics and then to proceed to resolve
conflicts, to the extent possible, within legal doctrines.61 This, in turn, forces a
need to critically examine the true social significance of the concepts of
normality and abnormality.62 With this all comes a fear, rational or irrational,
59 Sjef Gevers, Use of Genetic Data, Employment Data, Employment and Insurance:
InternationalPerspective, 7 BIOETHICS 126 (1993). See YvONNE M. CRIPPS, CONTROLLING
TECHNOLOGY: GENETICS, ENGINEERING AND THE LAW, Ch. 5 (1980).
60

Tony Sheldon, European Experts ProduceDrafton Bioethics, 309 BR. MED. J. 221 (1994).
Lori B. Andrews, The Randolph W. Thrower Symposium, Genetics and the Law,
Introduction,39 EMORY L.J. 619, 620 (1990).
61

62
Alexander M. Capron, Which Ills to Bear?: Reevaluating the 'Threat' of Modern
Genetics, 39 EMORY L.J. 665,693-94 (1990).
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that laws will be passed requiring everyone to submit to gene therapy or even,
as the case may warrant, to "provide personally identifiable genetic material
for purely scientific uses."63 Yet, interestingly, individuals are less likely to be
interested in knowing about their genetic profiles if they are obsessed with an
overriding fear that such knowledge will then be used (or misused) to punish
them. Society will thus be forced to develop both ethical and legal norms to
protect those members of society at higher risk for genetic discrimination. 64
Tens, if not hundreds, of new genetic screening tests will be in competition
with each other for introduction into routine clinical practice as the pace of the
Human Genome Project quickens. It is urged, consequently, that "new
strategies based on [a form of] general or generic consent ... be developed for
genetic screening-the aim [of which] would be to provide [adequate]
information to [thereby enable patients] to make informed decisions about
carrier screening yet prevent information overload that could lead to
misinformed consent." 65 The stakes in reproduction genetics are inevitably
high because they involve exercise of a right to decide whether or not to engage
in genetic testing, balanced by a coextensive right to refuse testing if a potential
harm-in terms of stigma, for example--outweighs the benefits derived from
it for the at-risk individual or his family.66
From a more positive side, universal access to the wide opportunities of
genetic services will allow persons "to act on the perception that it is good to
want to know about genetic risks."67 Accordingly, when the benefits of genetic
diagnosis and treatment become more evident over time, genetic information
will, in turn, become far less threatening and stigmatizing.
In order to meet these new challenges, law and science must march together
as full partners and not, as in the past, with law behind the scientific cadence.
All too often, as former Chief Justice Warren E. Burger has observed, "The law
does not search out as do science and medicine; it reacts to social needs and
demands." 68 It is thus vital for the law to develop an agenda for social change
and changing socio-political needs instead of simply reacting to change
itself--especially in the Age of the New Biology.69 In the final analysis, then, it
631d. at 695. See generallySidney A. Shapiro, Biotechnologyand the Design ofRegulation,

17 ECOLOGY L.Q. 1 (1990).
64
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Genoine is Mapped, 39 EMORY LJ. 747, 759 (1990).
65
Sherman Elias & George J. Annas, Generic Consent for Genetic Screening, 330 NEw
ENG. J. MED. 1611 (1994).
66
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67

Fletcher & Wertz, supra note 64.
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Warren E. Burger, Reflections on Law and ExperimentalMedicine, in 1 ETHICAL, LEGAL
AND SOCIAL CHALLENGES TO A BRAVE NEw WORLD 211 (George P. Smith, II ed., 1982).
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See George P. Smith, II, Biomedicine and Biomedical Ethics: De Lege Latta, De Lege

Ferenda,9 J. CoNTEMp'. HEALTH L. & POL'Y 233 (1993); George P. Smith, 11,Toward an
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is well to recognize that, "Each new power won by man is a power over man as
well."70
EPILOGUE

On March 16, 1995, the United States Equal Employment Opportunity
Commission concluded that the Americans With Disabilities Act will protect
healthy people carrying abnormal genes against employment
discrimination. 71 As such, this becomes the first pronouncement making it
illegal for an employer to discriminate against a worker on the basis of genetic
makeup. Interestingly, it does not address the central question of whether
insurance companies may deny health insurance to people with abnormal
genes. Both issues will ultimately have to be tested in the courts.

70

C. S. LEWIS, THE ABOUTION oF MAN 71 (MacMillan 1965) (1947).

71EEOC COMPLIANCE MANUAL, vol. 2, EEOC Order 915.002, Def. of the term
Disability (1995).

